RHD Gene Intron 3 PCR Primers for Blood Type Variant Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genotyping and blood cell antigen determination, particularly in distinguishing RHD*r′s or RHD*r′s-like variants from RHD*DIIIa and RHD*DIVa-2, face challenges due to antigenic and genetic complexity, leading to false positive readings and inability to discriminate between closely related alleles.
Innovation Solution
Development of specific PCR primers that amplify a portion of intron 3 of the RHD gene, capable of distinguishing RHD*r′s from RHD*DIIIa and RHD*DIVa-2, even under multiplex PCR conditions, using primers with tailored nucleotide sequences that minimize mismatches with the target template.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular methods detect polymorphisms in D-CE hybrid exon 3 locus of RHD to identify RHD*r′s, then detection sensitivity is improved, but false positive readings occur due to shared polymorphisms with RHD*DIIIa and RHD*DIVa-2 variants
Solution Approach 1:
The patent applies local quality by designing primers with specific nucleotide sequences that target unique regions within the D-CE hybrid exon 3 locus. The primers are engineered to match the specific polymorphic patterns of RHD*r′s while deliberately avoiding sequences shared with RHD*DIIIa and RHD*DIVa-2 variants, thereby achieving local specificity that resolves the false positive issue while maintaining detection sensitivity
Solution Approach 2:
The patent employs parameter changes by modifying primer nucleotide sequences to create optimal binding conditions. Specific nucleotide substitutions and additions are made to the primer sequences to enhance binding affinity for RHD*r′s target sequences while reducing cross-reactivity with other variants, thereby changing the detection parameters to achieve both sensitivity and reliability
2Measurement precision
If PCR primers are designed to amplify intron 3 of RHD gene for variant discrimination, then discrimination accuracy is improved, but primer design complexity increases due to need to minimize mismatches with target template
Solution Approach 1:
The patent applies preliminary action by conducting extensive in silico analysis and experimental validation during the primer design phase. The primers are pre-optimized to minimize mismatches with the target template sequence of RHD*r′s while maximizing specificity. This preliminary optimization ensures high discrimination accuracy without requiring complex post-PCR validation steps
Solution Approach 2:
The patent achieves universality by designing a set of primers that can discriminate between multiple RHD variants (RHD*r′s, RHD*DIIIa, RHD*DIVa-2) using a single PCR assay. The primers are designed to target conserved regions while detecting variant-specific polymorphisms, allowing one primer pair to perform multiple discrimination functions, thereby reducing overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively mitigates false positive readings and allows for accurate discrimination of RHD*r′s from closely related alleles, including a newly described variant RHD*DIIIa IVS3+3100G, enhancing the accuracy of blood typing and transfusion compatibility.
Implementation Method 1
specific PCR primers that amplify a portion of intron 3 of the RHD gene, capable of distinguishing RHD*r′s from RHD*DIIIa and RHD*DIVa-2
Implementation Method 2
amplify a portion of intron 3 of the RHD gene, capable of distinguishing RHD*r′s from RHD*DIIIa and RHD*DIVa-2, even under multiplex PCR conditions
Data Source
AI summary
The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r′s, RHD*DIIIa and RHD*DIVa-2. The method comprises amplifying by PCR a sample obtained from a human subject at intron 3 of the RHD gene locus. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention.